Physician profile
Omar Nadeem
NPI 1215170691
$190,702.68
in general payments reported to CMS, 2019-2025
19 companies · $59K in 2025
The $59K reported for 2025 was more than what 95% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $40K · 2021: $14K · 2022: $20K · 2023: $17K · 2024: $16K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $75K · Education: $6,098 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,530 · Food and Beverage: $2,983 · Travel and Lodging: $2,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $75,119.84 |
| Education | $6,098.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,530.00 |
| Food and Beverage | $2,982.59 |
| Travel and Lodging | $2,436.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $51,194.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $28,144.50 | 2021-2025 | Pomalyst, Abecma |
| Janssen Research & Development, LLC | $27,953.44 | 2024-2025 | Tecvayli |
| Janssen Biotech, INC. | $22,071.53 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Kite Pharma, INC. | $16,810.76 | 2025 | Yescarta |
| Genzyme Corporation | $15,613.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $8,641.96 | 2019-2023 | |
| Pfizer INC. | $5,793.10 | 2023 | |
| Adaptive Biotechnologies Corporation | $4,200.00 | 2020-2021 | |
| Glaxosmithkline, LLC. | $3,900.00 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $2,325.00 | 2020 | |
| Janssen Global Services, LLC | $1,515.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,134.99 | 2025 | |
| Janssen Scientific Affairs, LLC | $1,090.00 | 2023 | Darzalex |
| Adc Therapeutics America, INC. | $150.88 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $38.00 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Nadeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.